Skip to content

Banded Versus Conventional Laparoscopic Roux-en-Y (GABY)

International, Multi Centre, Open, Prospective, Randomized Study: Banded Versus Conventional Laparoscopic Roux-en-Y (GABY)

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01015469
Acronym
GABY
Enrollment
384
Registered
2009-11-18
Start date
2009-02-28
Completion date
2015-03-31
Last updated
2011-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid Obesity Requiring Bariatric Surgery

Keywords

bariatric, surgery, obesity, Roux-en-Y, gastric, medical device, bypass, adiposity, GaBP-Ring, BMI, banded, laparoscopic

Brief summary

Banded Versus Conventional Laparoscopic Roux-en-Y Gastric Bypass (GABY). The aim of this novel study is to evaluate, if an additional restrictive silastic ring can avoid dilation of the gastro-entero anastomosis and adjacent small bowel with consecutive better postoperative weight loss and significantly improved long-term weight maintenance. The study will not investigate the GaBP-Ring as medical product but the effect of the GaBP-Ring on weight loss in comparison to gastric bypass alone.

Detailed description

GABY is designed as an international, multi center, open, prospective, randomized study to compare two methods of bariatric surgery: Banded versus conventional laparoscopic Roux-en-Y gastric bypass. At least 16 international high volume centres of excellence in bariatric surgery and at least 384 patients (24 patients at each center) in total will be included into this study. At least 320 patients must have completed the study after 5 years. Surgery will be performed according to standardized operating protocol. The group A (control group) will follow the worldwide golden standard of bariatric surgery (gastric bypass). Patients randomised to group B will receive in addition a restrictive silastic ring. The ring is a launched medical product and is registered in the European Community.

Interventions

PROCEDUREConventional laparoscopic Roux-en-Y gastric bypass

Conventional laparoscopic Roux-en-Y gastric bypass

PROCEDUREconventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring

conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring (GaBP-Ring)

Sponsors

ClinTrio Ltd.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* BMI ≥ 40 kg /m2 to ≤ 50 kg/m2 * Eating habit: sweet eater and volume eater * Signed informed consent * Patients with one or more of the following comorbidities: Hypertension, Diabetes mellitus Type 2, Hyperlipidemia, Hyperuricemia, Sleep apnea, Degenerative diseases of: Spine osteochondrosis, hip, knee, feet

Exclusion criteria

* History of obesity surgery * History of major abdominal surgery with consecutive malabsorption (no resections of the stomach, small and large bowel (exception: appendectomy) * Patients not eligible to implement silastic ring size 6.5 cm * History of drug or alcohol abuse * History of major psychiatric illness conflicting with patient's compliance * History of recent or chronic steroid medication * Autoimmune disease * Inflammatory bowel disease or malabsorptive disease * Liver cirrhosis (CHILD B + C) * Active viral or bacterial disease (e.g. HIV, Hepatitis B or C, Tbc etc.) * Pregnant women or women with childbearing potential without efficient contraception * History of cancer in the last five years * Need of long-term anticoagulant medication for any reason * Any medication with ingredient ASA

Design outcomes

Primary

MeasureTime frame
postoperative reduction of body mass index (BMI) and maintenance related to used bariatric procedure0, 3, 6, 12 months and 2, 3, 4, 5 years

Countries

Austria, Belgium, Germany, Netherlands, Poland, Portugal, Saudi Arabia

Contacts

Primary ContactBurkhart Frankenberger
info@clintrio.com+49-511-38814-0
Backup ContactMaria Noraman
m.noraman@clintrio.com+49-511-38814-0

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026